Subtype
Malignant Reproductive System Neoplasm
CI-CAN-00001172Explore in graph →
2,804 active trials38 approved drugs186 evidence items
- NCIt
- C36076
Loading cancer entity…
Loading cancer entity…
Subtype
CI-CAN-00001172Explore in graph →
Clinical trials
12,158 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancersTerminated studies (1,473)
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT02112552 | Paclitaxel and Intraperitoneal Carboplatin Followed by Radiation Therapy in Treating Patients With Stage IIIC-IV Uterine Cancer | terminated | Phase 2 | 4 | Albert Einstein College of MedicineOTHER | 1 | Aug 29, 2023 | clinicaltrials |
| NCT00499174 | Observation or Radical Treatment in Patients With Prostate Cancer | terminated | N/A | 180 | NCIC Clinical Trials GroupNETWORK | 1 | Aug 23, 2023 | clinicaltrials |
| NCT01367301 | Radiation Therapy, Paclitaxel, and Carboplatin in Treating Patients With Uterine Cancer | terminated | N/A | 14 | Albert Einstein College of MedicineOTHER | 1 | Aug 21, 2023 | clinicaltrials |
| NCT04227275 | A Study of CART-PSMA-TGFβRDN in Patients With Metastatic Castration Resistant Prostate Cancer | terminated | Phase 1 | 16 | Tceleron Therapeutics, Inc.INDUSTRY | 1 | Aug 21, 2023 | clinicaltrials |
| NCT05489991 | A Study of TmPSMA-02 Chimeric Antigen Receptor (CAR) T-cells in Patients With Metastatic Castration Resistant Prostate Cancer (mCRPC) | terminated | Phase 1 / Phase 2 | 1 | Tceleron Therapeutics, Inc.INDUSTRY | 1 | Aug 18, 2023 | clinicaltrials |
| NCT01958580 | Gemcitabine Hydrochloride, Docetaxel, and Radiation Therapy in Treating Patients With Uterine Sarcoma That Has Been Removed By Surgery | terminated | N/A | 3 | Albert Einstein College of MedicineOTHER | 1 | Aug 16, 2023 | clinicaltrials |
| NCT00786682 | Docetaxel and Hydroxychloroquine in Treating Patients With Metastatic Prostate Cancer | terminated | Phase 2 | 11 | University of Medicine and Dentistry of New JerseyOTHER | 1 | Aug 14, 2023 | clinicaltrials |
| NCT00794339 | Phase II Trial of 64Cu-ATSM PET/CT in Cervical Cancer(ACRIN6682) | terminated | Phase 2 | 73 | American College of RadiologyOTHER | 1 | Aug 14, 2023 | clinicaltrials |
| NCT04066894 | Sacral Nerve Stimulation in Treating Low Anterior Resection Syndrome or Fecal Incontinence in Patients With Locally Advanced Rectal Cancer or Other Pelvic Cancer, the RESTORE Study | terminated | Phase 2 | 3 | M.D. Anderson Cancer CenterOTHER | 1 | Aug 14, 2023 | clinicaltrials |
| NCT04575766 | A Study of FT-7051 in Men With MCRPC | terminated | Phase 1 | 25 | Novo Nordisk A/SINDUSTRY | 1 | Aug 9, 2023 | clinicaltrials |
| NCT00968799 | Hyperthermic Intraoperative Intraperitoneal Chemotherapy of Recurrent Ovarian Cancer - A Feasibility Study | terminated | N/A | 6 | Cantonal Hospital of St. GallenOTHER | 1 | Aug 8, 2023 | clinicaltrials |
| NCT00651326 | Androgen Suppression and Radiation With/Out Docetaxel in High-Risk Localized Prostate Cancer(DART) | terminated | Phase 3 | 48 | NCIC Clinical Trials GroupNETWORK | 1 | Aug 4, 2023 | clinicaltrials |
| NCT02059265 | Dasatinib in Treating Patients With Recurrent or Persistent Ovarian, Fallopian Tube, Endometrial or Peritoneal Cancer | terminated | Phase 2 | 35 | National Cancer Institute (NCI)NIH | 1 | Aug 1, 2023 | clinicaltrials |
| NCT05010759 | Study of Focal Ablation of the Prostate With NanoTherm® Therapy System for Intermediate-Risk Prostate Cancer | terminated | N/A | 3 | MagForce USAINDUSTRY | 1 | Aug 1, 2023 | clinicaltrials |
| NCT02341118 | Capturing BRCA1/2 Mutational Status in Women With High Grade Serous Ovarian Cancer and Impact on Clinical Outcome. | terminated | — | 109 | University Health Network, TorontoOTHER | 1 | Jul 27, 2023 | clinicaltrials |
| NCT04424641 | A Study on the Safety of GEN1044 (DuoBody®-CD3x5T4) in Patients With Malignant Solid Tumors | terminated | Phase 1 / Phase 2 | 48 | GenmabINDUSTRY | 4 | Jul 25, 2023 | clinicaltrials |
| NCT05584332 | A Phase Ⅲ Study to Evaluate the Efficacy, Immunogenicity, Safety of Quadrivalent HPV Recombinant Vaccine in Chinese Healthy Females | terminated | Phase 3 | 3,131 | Shanghai Bovax Biotechnology Co., Ltd.INDUSTRY | 1 | Jul 21, 2023 | clinicaltrials |
| NCT00788125 | Dasatinib, Ifosfamide, Carboplatin, and Etoposide in Treating Young Patients With Metastatic or Recurrent Malignant Solid Tumors | terminated | Phase 1 / Phase 2 | 7 | City of Hope Medical CenterOTHER | 1 | Jul 14, 2023 | clinicaltrials |
| NCT04541225 | Study of NUV-422 in Adults With Recurrent or Refractory High-grade Gliomas and Solid Tumors | terminated | Phase 1 | 74 | Nuvation Bio Inc.INDUSTRY | 1 | Jul 14, 2023 | clinicaltrials |
| NCT03927573 | Study With Bispecific Antibody Engaging T-cells, in Patients With Progressive Cancer Diseases With Positive PSCA Marker | terminated | Phase 1 | 23 | AvenCell Europe GmbHINDUSTRY | 1 | Jul 10, 2023 | clinicaltrials |
| NCT04163094 | Ovarian Cancer Treatment With a Liposome Formulated mRNA Vaccine in Combination With (Neo-)Adjuvant Chemotherapy(OLIVIA) | terminated | Phase 1 | 8 | University Medical Center GroningenOTHER | 1 | Jun 29, 2023 | clinicaltrials |
| NCT02640534 | Investigation of Metformin in Patients With Castration Resistant Prostate Cancer in Combination With Enzalutamide vs. Enzalutamide Alone | terminated | Phase 2 | 169 | Swiss Cancer InstituteOTHER | 1 | Jun 27, 2023 | clinicaltrials |
| NCT01992861 | MRI and PET Imaging in Predicting Treatment Response in Patients With Stage IB-IVA Cervical Cancer | terminated | — | 51 | University of WashingtonOTHER | 3 | Jun 26, 2023 | clinicaltrials |
| NCT00002668 | Pain Control in Patients With Recurrent or Metastatic Breast or Prostate Cancer | terminated | N/A | 13 | Eastern Cooperative Oncology GroupNETWORK | 4 | Jun 22, 2023 | clinicaltrials |
| NCT01133756 | E7080 in Combination With Carboplatin + Gemcitabine Versus Carboplatin + Gemcitabine Alone as Second Line Therapy in Patients With Platinum-Sensitive Recurrent Ovarian Cancer by CA125 | terminated | Phase 1 / Phase 2 | 7 | Eisai Inc.INDUSTRY | 1 | Jun 22, 2023 | clinicaltrials |
| NCT01326312 | Effect of GTx-758 on Total and Free Testosterone Levels in Men With Prostate Cancer(GTx758) | terminated | Phase 2 | 159 | GTxINDUSTRY | 1 | Jun 22, 2023 | clinicaltrials |
| NCT03824704 | A Study to Evaluate Rucaparib in Combination With Nivolumab in Patients With Selected Solid Tumors (ARIES) | terminated | Phase 2 | 1 | pharmaand GmbHINDUSTRY | 1 | Jun 12, 2023 | clinicaltrials |
| NCT02516670 | Docetaxel With or Without Ascorbic Acid in Treating Patients With Metastatic Prostate Cancer | terminated | Phase 2 | 50 | Sidney Kimmel Comprehensive Cancer Center at Johns HopkinsOTHER | 1 | Jun 7, 2023 | clinicaltrials |
| NCT03553212 | Twice High Dose External Beam Radiotherapy by Image-guided Tomotherapy for Organ-confined Prostate Cancer Treatment Emulating High Dose Radiation (HDR) Brachytherapy(THRIP) | terminated | N/A | 2 | Istituto Romagnolo per lo Studio dei Tumori Dino Amadori IRST S.r.l. IRCCSOTHER | 1 | May 30, 2023 | clinicaltrials |
| NCT03535675 | Muscadine Plus (MPX) In Men With Prostate Cancer | terminated | Phase 3 | 59 | Sidney Kimmel Comprehensive Cancer Center at Johns HopkinsOTHER | 1 | May 22, 2023 | clinicaltrials |
| NCT04843319 | To Determine an Effective Dose of VERU-100 for the Treatment of Advanced Prostate Cancer(VERU-100) | terminated | Phase 1 / Phase 2 | 24 | Veru Inc.INDUSTRY | 1 | May 19, 2023 | clinicaltrials |
| NCT04077021 | First-in-human Study of CCW702 in Patients With Metastatic Castration Resistant Prostate Cancer | terminated | Phase 1 | 22 | Calibr, a division of Scripps ResearchOTHER | 1 | May 12, 2023 | clinicaltrials |
| NCT02968784 | Focal ExAblate MR-Guided Focused Ultrasound Treatment for Management of Organ-Confined Intermediate Risk Prostate Cancer | terminated | N/A | 53 | InSightecINDUSTRY | 3 | May 9, 2023 | clinicaltrials |
| NCT03400943 | Assess Safety and Efficacy of Vilaprisan in Subjects With Uterine Fibroids (ASTEROID 3) | terminated | Phase 3 | 93 | BayerINDUSTRY | 9 | May 3, 2023 | clinicaltrials |
| NCT04073485 | Microwave Ablation for Uterine Fibroids | terminated | N/A | 6 | Chinese University of Hong KongOTHER | 1 | May 3, 2023 | clinicaltrials |
| NCT03574194 | Methionine-Restricted Diet to Potentiate The Effects of Radiation Therapy | terminated | N/A | 8 | West Virginia UniversityOTHER | 1 | Apr 25, 2023 | clinicaltrials |
| NCT03919214 | Hypertension Management in Cancer Patients | terminated | N/A | 4 | Duke UniversityOTHER | 1 | Apr 19, 2023 | clinicaltrials |
| NCT03642990 | NR in Chemo-induced Peripheral Neuropathy | terminated | Phase 2 | 5 | Donna Hammond, PhDOTHER | 1 | Apr 12, 2023 | clinicaltrials |
| NCT04085991 | Two TraCer PositROn EmiSSion Tomography ComBination for Efficacy EstimatiOn of Prostate Specific Membrane Antigen Radioligand Therapy in Patients With Metastatic Prostate Cancer(CROSSBOW) | terminated | Phase 2 | 11 | Sir Mortimer B. Davis - Jewish General HospitalOTHER | 1 | Apr 12, 2023 | clinicaltrials |
| NCT03642132 | Avelumab and Talazoparib in Untreated Advanced Ovarian Cancer (JAVELIN OVARIAN PARP 100) | terminated | Phase 3 | 79 | PfizerINDUSTRY | 10 | Apr 6, 2023 | clinicaltrials |
| NCT02844647 | Hyperpolarized Carbon-13 Imaging of Metastatic Prostate Cancer | terminated | Phase 1 | 2 | Sunnybrook Health Sciences CentreOTHER | 1 | Mar 28, 2023 | clinicaltrials |
| NCT03440879 | Androgen Deprivation Therapy Muscle Protein Metabolism and Blood Glucose | terminated | N/A | 23 | Norwegian School of Sport SciencesOTHER | 1 | Mar 27, 2023 | clinicaltrials |
| NCT04423913 | Safety, Tolerability, Distribution & Dose Effect of Neoadjuvant Transarterial Chemoembolization With Doxorubicin in Prostate Cancer Patients Before Radical Prostatectomy(CAPEMCHAR) | terminated | Phase 2 | 12 | Centre Hospitalier Universitaire de NīmesOTHER | 1 | Mar 27, 2023 | clinicaltrials |
| NCT02291055 | A Study of ADXS11-001 or MEDI4736 Alone or Combination In Cervical or Human Papillomavirus (HPV)+ Head & Neck Cancer | terminated | Phase 1 / Phase 2 | 75 | Advaxis, Inc.INDUSTRY | 1 | Mar 20, 2023 | clinicaltrials |
| NCT01709734 | A 2 Part, Phase 2 Trial of Galeterone in the Treatment of Castration Resistant Prostate Cancer(ARMOR2) | terminated | Phase 2 | 126 | LTN PHARMACEUTICALS, INC.INDUSTRY | 2 | Mar 15, 2023 | clinicaltrials |
| NCT02438007 | A Study of Galeterone Compared to Enzalutamide In Men Expressing Androgen Receptor Splice Variant-7 mRNA (AR-V7) Metastatic CRPC(ARMOR3-SV) | terminated | Phase 3 | 953 | LTN PHARMACEUTICALS, INC.INDUSTRY | 8 | Mar 15, 2023 | clinicaltrials |
| NCT02853604 | Study of ADXS11-001 in Participants With High Risk Locally Advanced Cervical Cancer(AIM2CERV) | terminated | Phase 3 | 110 | Advaxis, Inc.INDUSTRY | 14 | Mar 14, 2023 | clinicaltrials |
| NCT03439033 | Comparison Study of PET/CT or PET/MRI Imaging to Magnetic Resonance Imaging (MRI) Alone in Men With Prostate Cancer | terminated | Phase 2 | 273 | Weill Medical College of Cornell UniversityOTHER | 1 | Mar 13, 2023 | clinicaltrials |
| NCT03921996 | Extended Pelvic Lymph Node Dissection vs. no Pelvic Lymph Node Dissection at Radical Prostatectomy for intermediate-and High-risk Prostate Cancer | terminated | Phase 3 | 57 | Swiss Cancer InstituteOTHER | 1 | Mar 9, 2023 | clinicaltrials |
Data updated 23 days agoSource updated Aug 29, 2023source: clinicaltrials